Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016
Published Oct 12, 2016
82 pages — Published Oct 12, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease Pipeline Review, H2 2016, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 2 and 6 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 4 molecules, respectively for Chagas Disease.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)
&

  
Source:
Document ID
GMDHC8523IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Chagas Disease (American Trypanosomiasis) Overview91
Therapeutics Development102
  Pipeline Products for Chagas Disease (American Trypanosomiasis) Overview101
  Pipeline Products for Chagas Disease (American Trypanosomiasis) Comparative Analysis111
Chagas Disease (American Trypanosomiasis) Therapeutics under Development by Companies121
Chagas Disease (American Trypanosomiasis) Therapeutics under Investigation by Universities/Institutes131
Chagas Disease (American Trypanosomiasis) Pipeline Products Glance143
  Late Stage Products141
  Clinical Stage Products151
  Early Stage Products161
Chagas Disease (American Trypanosomiasis) Products under Development by Companies171
Chagas Disease (American Trypanosomiasis) Products under Investigation by Universities/Institutes181
Chagas Disease (American Trypanosomiasis) Companies Involved in Therapeutics Development198
  Bayer AG191
  Eisai Co., Ltd.201
  GlaxoSmithKline Plc211
  Grupo Praxis Pharmaceutical SA221
  KaloBios Pharmaceuticals, Inc.231
  Merck &Co., Inc.241
  Novartis AG251
  Sanofi261
Chagas Disease (American Trypanosomiasis) Therapeutics Assessment279
  Assessment by Monotherapy Products271
  Assessment by Target282
  Assessment by Mechanism of Action302
  Assessment by Route of Administration322
  Assessment by Molecule Type342
Drug Profiles3636
  benznidazol Drug Profile361
  benznidazole Drug Profile371
  chagas disease (bivalent) vaccine Drug Profile381
  chagas disease vaccine Drug Profile391
  chagas disease vaccine Drug Profile401
  Chagas disease vaccine Drug Profile411
  Cz-007 Drug Profile421
  Cz-008 Drug Profile431
  EPLBS-1246 Drug Profile441
  EPLBS-967 Drug Profile451
  fexinidazole Drug Profile462
  fosravuconazole Drug Profile482
  GNF-6702 Drug Profile501
  K-777 Drug Profile512
  NEU-321 Drug Profile531
  nifurtimox Drug Profile541
  nifurtimox SR Drug Profile551
  posaconazole Drug Profile562
  SAR-114137 Drug Profile581
  Small Molecule to Inhibit Cruzipain for Chagas Disease Drug Profile591
  Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis Drug Profile601
  Small Molecules for Chagas Disease Drug Profile611
  Small Molecules for Chagas Disease Drug Profile621
  Small Molecules for Chagas Disease Drug Profile631
  Small Molecules for Chagas Disease Drug Profile641
  Small Molecules for Chagas Disease Drug Profile651
  Small Molecules for Infectious Diseases Drug Profile661
  Small Molecules for Infectious Diseases Drug Profile671
  Small Molecules for Protozoal Infections Drug Profile681
  Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease Drug Profile691
  Small Molecules to Inhibit Proline Racemase for Chagas Disease Drug Profile701
  VNI Drug Profile711
Chagas Disease (American Trypanosomiasis) Dormant Projects721
Chagas Disease (American Trypanosomiasis) Discontinued Products731
Chagas Disease (American Trypanosomiasis) Product Development Milestones747
  Featured News &Press Releases741
    Apr 11, 2016: KaloBios Announces New Product Pricing Model741
    Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease741
    May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease751
    Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease761
    Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy771
    May 03, 2013: Funding boost for GSK s open innovation research into diseases affecting the developing world781
    Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease791
    Mar 12, 2012: DNDi Receives 2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease801
Appendix812
  Methodology811
  Coverage811
  Secondary Research811
  Primary Research811
  Expert Panel Validation811
  Contact Us811
  Disclaimer821

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016" Oct 12, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chagas-Disease-American-Trypanosomiasis-Pipeline-Review-H2-2016-2088-16652>
  
APA:
Global Markets Direct - Market Research. (2016). Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2016 Oct 12, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chagas-Disease-American-Trypanosomiasis-Pipeline-Review-H2-2016-2088-16652>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.